Kiniksa Pharmaceuticals International (KNSA) Non-Current Deffered Revenue (2018 - 2026)

Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue history runs 6 years deep, the most recent figure standing at $31.8 million for Q1 2026.

• Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $31.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.8 million (changed 0.0% YoY) and the FY2025 annual result came in at $31.8 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue was $31.8 million for Q1 2026 at Kiniksa Pharmaceuticals International, roughly flat from $31.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $31.8 million in Q4 2024 and bottomed at $11.8 million in Q2 2024.
• A 5-year average of $19.1 million and a median of $12.0 million in 2023 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue dropped 16.38% — and 2025, when it soared 169.61%.
• Kiniksa Pharmaceuticals International's Non-Current Deffered Revenue stood at $12.0 million in 2022, then changed by 0.0% to $12.0 million in 2023, then soared by 165.09% to $31.8 million in 2024, then changed by 0.0% to $31.8 million in 2025, then changed by 0.0% to $31.8 million in 2026.
• Business Quant data shows KNSA's Non-Current Deffered Revenue at $31.8 million in Q1 2026, $31.8 million in Q4 2025, and $31.8 million in Q3 2025.